CIZUMAB™ 400
Brand Name: CIZUMAB™ 400
Composition:
Each ml of concentrate contains 25 mg of Bevacizumab.
The 16 ml vial contains:
Bevacizumab (r-DNA origin): 400 mg
Trehalose Dihydrate USP: 960 mg
Monobasic Sodium Phosphate (Monohydrate) IP: 92.8 mg
Dibasic Sodium Phosphate (Anhydrous) USP: 19.2 mg
Polysorbate 20 IP: 6.4 mg
Water for Injections IP: q.s. to 16 ml
Product Description
Medical Info
CIZUMAB™ 400 (Bevacizumab) is a prescription oncology medication supplied as a 16 ml concentrate for solution, containing a total of 400 mg of the active antibody. This sterile concentrate is intended strictly for intravenous administration only after proper dilution as directed. Bevacizumab is a targeted therapy that works by inhibiting the growth of new blood vessels that supply tumor cells. CIZUMAB™ 400 requires careful storage between +2°C to +8°C, and it must never be frozen or shaken. It must always be protected from light. Refer to the complete package insert for comprehensive dosage, dilution, and critical administration guidance.
Storage & Safety
Precautions & Warnings
Reconstitute only with the prescribed quantity of clean drinking water. Shake well before each use. Complete the full course as prescribed. Discard any unused suspension after 7 days of reconstitution.
Storage
Store in a cool, dry place below 25°C. Protect from light and moisture. Refrigeration after reconstitution is preferred.
Status
Keep all medicines out of reach of children.
